NCT07052994View on ClinicalTrials.gov

A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia Patients

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

December 31, 2032

Study Completion Date

December 31, 2034

Conditions
Pediatric Acute Leukemia
Interventions
DRUG

Revumenib

Given by IV

DRUG

Cytrabine

Given by IV

DRUG

Daunorubicin

Given by IV

Trial Locations (1)

77030

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER